08: Antibody Response to RSV Vaccines in Immunocompromised Adults

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/81/b3/3d/81b33d4a-7deb-1ca1-4b29-abc8ae3dd326/mza_16276549136574942800.jpg/600x600bb.jpg

Transplant & Oncology ID: Literature Dives

Transplant & Oncology ID

9 episodes

2 days ago

Discover Transplant & Oncology ID: Literature Dives, the podcast dedicated to breaking down the latest research in transplant and oncology infectious diseases in near real-time. Perfect for healthcare professionals, researchers, and enthusiasts, our episodes feature deep dives into groundbreaking studies and evidence-based practices. Stay informed on the cutting-edge science shaping infectious disease management in immunocompromised patients. Follow us to keep up with regular episodes! Created with NotebookLM so there may be mistakes and/or errors.

Medicine

Health & Fitness

RSS

All content for Transplant & Oncology ID: Literature Dives is the property of Transplant & Oncology ID and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/42652512/42652512-1734020663234-fbef8565cb184.jpg

08: Antibody Response to RSV Vaccines in Immunocompromised Adults

Transplant & Oncology ID: Literature Dives

12 minutes 27 seconds

10 months ago

08: Antibody Response to RSV Vaccines in Immunocompromised Adults

This study investigates the antibody response to respiratory syncytial virus (RSV) vaccines in immunocompromised individuals. Researchers measured antibody levels in a cohort of immunocompromised adults after receiving either an adjuvanted or non-adjuvanted RSV vaccine. Results showed heterogeneous antibody responses, with a significant portion not achieving seroconversion or a high-titer neutralization threshold. The adjuvanted vaccine showed better results. Study limitations included a small sample size and lack of cellular data. The findings suggest a need for further investigation into optimizing RSV vaccination strategies for immunocompromised populations.

Created with NotebookLM by Google so there may be mistakes and/or errors.

PMID: 39786402

Karaba AH, Hage C, Sengsouk I, et al. Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons. JAMA 2024.